Product Description
Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics. Local anesthetics are used in regional anesthesia, epidural anesthesia, spinal anesthesia, and local infiltration. Local anesthetics generally block the generation of the action potential in nerve cells by increasing the threshold for electrical excitation. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK532883/)
Mechanisms of Action: Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Anastesia Related
Known Adverse Events: Hypotension | Paralysis | Hypoventilation
Company: Pacira
Company Location: PARSIPPANY NJ 07054
Company CEO: David Stack
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Egypt, United States
Active Clinical Trial Count: 17
Highest Development Phases
Phase 3: Acute Respiratory Distress Syndrome|Agnosia|Anesthesia Related|Back Pain|Bunion|Chronic Pain|Dupuytren Contracture|Hallux Valgus|Osteoarthritis, Knee|Pain, Postoperative|Shoulder Pain
Phase 2: Other
Phase 1: Healthy Volunteers|Pain Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BULI-201 | P2 |
Not yet recruiting |
Pain, Postoperative |
2026-09-28 |
|
| J17157 | P3 |
Recruiting |
Agnosia |
2025-09-01 |
|
| 402-C-125 | P1 |
Recruiting |
Pain, Postoperative |
2025-07-01 |
|
| Pro2022001580 | P3 |
Recruiting |
Pain, Postoperative |
2025-01-11 |